<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Biomed Sci</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Biomed. Sci</journal-id>
<journal-title-group>
<journal-title>Journal of Biomedical Science</journal-title>
</journal-title-group>
<issn pub-type="ppub">1021-7770</issn>
<issn pub-type="epub">1423-0127</issn>
<publisher>
<publisher-name>BioMed Central</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28711067</article-id>
<article-id pub-id-type="pmc">5513211</article-id>
<article-id pub-id-type="publisher-id">352</article-id>
<article-id pub-id-type="doi">10.1186/s12929-017-0352-x</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>PA-6 inhibits inward rectifier currents carried by V93I and D172N gain-of-function K<sub>IR</sub>2.1 channels, but increases channel protein expression</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ji</surname>
<given-names>Yuan</given-names>
</name>
<address>
<email>y.ji@umcutrecht.nl</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Veldhuis</surname>
<given-names>Marlieke G.</given-names>
</name>
<address>
<email>veldhuismarlieke@gmail.com</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zandvoort</surname>
<given-names>Jantien</given-names>
</name>
<address>
<email>mail.jzandvoort@gmail.com</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Romunde</surname>
<given-names>Fee L.</given-names>
</name>
<address>
<email>feeromunde@hotmail.com</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Houtman</surname>
<given-names>Marien J. C.</given-names>
</name>
<address>
<email>m.j.c.houtman@umcutrecht.nl</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Duran</surname>
<given-names>Karen</given-names>
</name>
<address>
<email>K.J.Duran@umcutrecht.nl</email>
</address>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>van Haaften</surname>
<given-names>Gijs</given-names>
</name>
<address>
<email>G.vanHaaften@umcutrecht.nl</email>
</address>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zangerl-Plessl</surname>
<given-names>Eva-Maria</given-names>
</name>
<address>
<email>eva-maria.zangerl@univie.ac.at</email>
</address>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Takanari</surname>
<given-names>Hiroki</given-names>
</name>
<address>
<email>takanari.hiroki@tokushima-u.ac.jp</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stary-Weinzinger</surname>
<given-names>Anna</given-names>
</name>
<address>
<email>anna.stary@univie.ac.at</email>
</address>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>van der Heyden</surname>
<given-names>Marcel A. G.</given-names>
</name>
<address>
<phone>31 30 2538901</phone>
<email>m.a.g.vanderheyden@umcutrecht.nl</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000000090126352</institution-id><institution-id institution-id-type="GRID">grid.7692.a</institution-id><institution>Department of Medical Physiology, Division of Heart and Lungs, </institution><institution>University Medical Center Utrecht, </institution></institution-wrap>Yalelaan 50, 3584 CM Utrecht, The Netherlands </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000000090126352</institution-id><institution-id institution-id-type="GRID">grid.7692.a</institution-id><institution>Center for Molecular Medicine, Department of Medical Genetics, </institution><institution>University Medical Center Utrecht, </institution></institution-wrap>Utrecht, The Netherlands </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2286 1424</institution-id><institution-id institution-id-type="GRID">grid.10420.37</institution-id><institution>Department of Pharmacology and Toxicology, </institution><institution>University of Vienna, </institution></institution-wrap>Vienna, Austria </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>15</day>
<month>7</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>15</day>
<month>7</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>24</volume>
<elocation-id>44</elocation-id>
<history>
<date date-type="received">
<day>26</day>
<month>4</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>7</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s). 2017</copyright-statement>
<license license-type="OpenAccess">
<license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<sec>
<title>Background</title>
<p id="Par1">The inward rectifier potassium current I<sub>K1</sub> contributes to a stable resting membrane potential and phase 3 repolarization of the cardiac action potential. <italic>KCNJ2</italic> gain-of-function mutations V93I and D172N associate with increased I<sub>K1</sub>, short QT syndrome type 3 and congenital atrial fibrillation. Pentamidine-Analogue 6 (PA-6) is an efficient (IC<sub>50</sub> = 14 nM with inside-out patch clamp methodology) and specific I<sub>K1</sub> inhibitor that interacts with the cytoplasmic pore region of the K<sub>IR</sub>2.1 ion channel, encoded by <italic>KCNJ2</italic>. At 10 μM, PA-6 increases wild-type (WT) K<sub>IR</sub>2.1 expression in HEK293T cells upon chronic treatment. We hypothesized that PA-6 will interact with and inhibit V93I and D172N K<sub>IR</sub>2.1 channels, whereas impact on channel expression at the plasma membrane requires higher concentrations.</p>
</sec>
<sec>
<title>Methods</title>
<p id="Par2">Molecular modelling was performed with the human K<sub>IR</sub>2.1 closed state homology model using FlexX. WT and mutant K<sub>IR</sub>2.1 channels were expressed in HEK293 cells. Patch-clamp single cell electrophysiology measurements were performed in the whole cell and inside-out mode of the patch clamp method. K<sub>IR</sub>2.1 expression level and localization were determined by western blot analysis and immunofluorescence microscopy, respectively.</p>
</sec>
<sec>
<title>Results</title>
<p id="Par3">PA-6 docking in the V93I/D172N double mutant homology model of K<sub>IR</sub>2.1 demonstrated that mutations and drug-binding site are &gt;30 Å apart. PA-6 inhibited WT and V93I outward currents with similar potency (IC<sub>50</sub> = 35.5 and 43.6 nM at +50 mV for WT and V93I), whereas D172N currents were less sensitive (IC<sub>50</sub> = 128.9 nM at +50 mV) using inside-out patch-clamp electrophysiology. In whole cell mode, 1 μM of PA-6 inhibited outward I<sub>K1</sub> at −50 mV by 28 ± 36%, 18 ± 20% and 10 ± 6%, for WT, V93I and D172N channels respectively. Western blot analysis demonstrated that PA-6 (5 μM, 24 h) increased K<sub>IR</sub>2.1 expression levels of WT (6.3 ± 1.5 fold), and V93I (3.9 ± 0.9) and D172N (4.8 ± 2.0) mutants. Immunofluorescent microscopy demonstrated dose-dependent intracellular K<sub>IR</sub>2.1 accumulation following chronic PA-6 application (24 h, 1 and 5 μM).</p>
</sec>
<sec>
<title>Conclusions</title>
<p id="Par4">1) <italic>KCNJ2</italic> gain-of-function mutations V93I and D172N in the K<sub>IR</sub>2.1 ion channel do not impair PA-6 mediated inhibition of I<sub>K1</sub>, 2) PA-6 elevates K<sub>IR</sub>2.1 protein expression and induces intracellular K<sub>IR</sub>2.1 accumulation, 3) PA-6 is a strong candidate for further preclinical evaluation in treatment of congenital SQT3 and AF.</p>
</sec>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>I<sub>K1</sub></kwd>
<kwd>K<sub>IR</sub>2.1</kwd>
<kwd>Atrial fibrillation</kwd>
<kwd>Short QT syndrome</kwd>
<kwd>Drugs</kwd>
<kwd>PA-6</kwd>
<kwd>Trafficking</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002860</institution-id>
<institution>China Sponsorship Council</institution>
</institution-wrap>
</funding-source>
<award-id>n.a.</award-id>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2017</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Background</title>
<p id="Par17">In the heart, inward rectifier potassium currents (I<sub>K1</sub>) contribute to stabilization of the resting membrane potential of contractile cardiomyocytes and participate in the final phase of repolarization of the action potential [<xref ref-type="bibr" rid="CR1">1</xref>]. Gain-of-function mutations in the <italic>KCNJ2</italic> gene, that encodes K<sub>IR</sub>2.1 protein underlying I<sub>K1</sub>, associate with ventricular (short QT syndrome type 3 (SQT3)) and atrial (congenital atrial fibrillation (AF)) phenotypes. D172N and K346T are linked to SQT3, whereas V93I associates with congenital AF [<xref ref-type="bibr" rid="CR2">2</xref>–<xref ref-type="bibr" rid="CR4">4</xref>]. E299V and M301K have been linked to both SQT3 and AF [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>].</p>
<p id="Par18">Congenital SQT syndrome is diagnosed in the presence of a QTc interval equal or less than 330 ms, and may be diagnosed at a QTc of less than 360 ms when other conditions apply, like a pathologic mutation or a family history of SQT [<xref ref-type="bibr" rid="CR7">7</xref>]. Congenital SQT can either be caused to excessive repolarization capacity (SQT1-3), or due to decreased depolarization capacity (SQT4-7), and is associated with high risk for sudden cardiac death and therefore implantable cardioverter-defibrillator (ICD) implantation is indicated [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. However, pharmacotherapy may be beneficial in patients that are unsuitable for ICD therapy (e.g. young children), those that refuse ICD implantation or for bridging the time to ICD implantation [<xref ref-type="bibr" rid="CR10">10</xref>]. Some drugs are indeed able to inhibit currents produced by K<sub>v</sub>11.1, K<sub>V</sub>7.1 and K<sub>IR</sub>2.1 channels bearing gain-of-function mutations associated with SQT1, SQT2 and SQT3, respectively [<xref ref-type="bibr" rid="CR11">11</xref>–<xref ref-type="bibr" rid="CR14">14</xref>].</p>
<p id="Par19">AF is associated with increased risk for stroke and heart failure [<xref ref-type="bibr" rid="CR15">15</xref>]. Action potential lengthening drugs, e.g. targeting the delayed rectifier (I<sub>Kr</sub>), or drugs increasing atrial fibrillation cycle length (sodium current (I<sub>Na</sub>) blockers), have the potential to counteract AF [<xref ref-type="bibr" rid="CR16">16</xref>]. Inhibition of the acetylcholine activated inward rectifier potassium current (I<sub>KAch</sub>) channel, closely related to the I<sub>K1</sub> channel, has been proposed as an effective treatment in AF [<xref ref-type="bibr" rid="CR17">17</xref>]. Also I<sub>K1</sub> inhibiting compounds, like chloroquine, display anti-AF activity in animal models [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>].</p>
<p id="Par20">We have developed a new I<sub>K1</sub> inhibiting compound, named PA-6, recently [<xref ref-type="bibr" rid="CR20">20</xref>]. After crossing the plasma membrane, PA-6 can enter the I<sub>K1</sub> channel from the cytoplasmic side, will bind to the channel by lipophilic interactions and hydrogen bonds to residues E224, D259 and E299, and subsequently inhibits inward and outward potassium current with an IC<sub>50</sub> in the low nanomolar range [<xref ref-type="bibr" rid="CR20">20</xref>]. Recently, we demonstrated that PA-6 lengthens action potential duration, atrial fibrillation cycle length and cardioverts goats with rapid pacing induced AF to sinus rhythm [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Interestingly, some ion channel inhibitors are able to increase channel expression [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR22">22</xref>], or restore normal plasma membrane expression of trafficking defective mutant channels [<xref ref-type="bibr" rid="CR23">23</xref>–<xref ref-type="bibr" rid="CR25">25</xref>], probably by stabilizing the channel structure as a result of their direct interaction. Also PA-6 is able to increase expression of wild-type (WT) K<sub>IR</sub>2.1 channels [<xref ref-type="bibr" rid="CR20">20</xref>].</p>
<p id="Par21">We hypothesized that PA-6 inhibits I<sub>K1</sub> channels that are formed by gain-of-function K<sub>IR</sub>2.1 channel proteins and thus can be considered as a candidate drug in treating SQT3 and congenital AF.</p>
</sec>
<sec id="Sec2">
<title>Methods</title>
<sec id="Sec3">
<title>Molecular modelling</title>
<p id="Par22">Docking of compound PA-6 was conducted using the previously constructed closed state homology model of the human K<sub>IR</sub>2.1 channel [<xref ref-type="bibr" rid="CR20">20</xref>]. In silico mutations of residues V93I and D172N were generated with SwissPdbViewer [<xref ref-type="bibr" rid="CR26">26</xref>]. Compound PA-6 was generated as described previously [<xref ref-type="bibr" rid="CR20">20</xref>]. The docking program FlexX (part of the LeadIT software package version 2.0.1 (BioSolveIT GmbH, St Augustin, Germany) was used for docking. The binding site was specified selecting the carboxylic acids of the Glu224 residues from all four subunits. The radius of the binding site was set to 20 Å. Default settings of FlexX were applied for protonation and torsion angles. The ChemScore scoring function of FlexX was applied and the top 10 docking solutions were saved for analysis.</p>
</sec>
<sec id="Sec4">
<title>KCNJ2 constructs</title>
<p id="Par23">Mutations V93I and D172N were engineered into a human <italic>KCNJ2-</italic>pcDNA3 expression construct [<xref ref-type="bibr" rid="CR27">27</xref>], using the QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) and custom designed primers. The presence of the introduced mutations was confirmed by Sanger sequencing.</p>
</sec>
<sec id="Sec5">
<title>Patch-clamp electrophysiology</title>
<p id="Par24">HEK293T cells were transfected with WT, V93I or D172N constructs together with a GFP expression construct to enable detection of transfected cells. Inside-out patch clamp measurements were made using a HEKA EPC-10 Double Plus amplifier controlled by PatchMaster 2.10 software (HEKA, Lambrecht/Pfalz, Germany) at 21 °C. To record WT, V93I and D172N K<sub>IR</sub>2.1 currents, inside-out patch-clamp measurements were performed using a ramp protocol ranging from −100 to +100 mV in 5 s from a holding potential of −40 mV. Excised patches were placed in close proximity to the inflow region of the perfusion chamber. Bath solution contained 125 mM KCl, 4 mM EDTA (2K), 7.2 mM K<sub>2</sub>HPO<sub>4</sub>, 2.8 mM KH<sub>2</sub>PO<sub>4</sub>, pH 7.20/KOH. Pipette solution contained 145 mM KCl, 1 mM CaCl<sub>2</sub>, 5 mM HEPES, pH 7.40/KOH. Measurements were started following washout of polyamines/Mg<sup>2+</sup> from the channel pore observed by the disappearance of current rectification. For IC<sub>50</sub> curves, fractional block at −80 and +50 mV was determined by dividing current levels obtained with PA-6 containing solutions by current levels of control traces recorded in the absence of PA-6.</p>
<p id="Par25">Whole cell patch clamp measurements were done as described before [<xref ref-type="bibr" rid="CR28">28</xref>] using an AxoPatch 200B amplifier controlled by pClamp9 software (Molecular devices, Sunnyvale, CA, USA) at 21 °C. Whole cell I<sub>KIR2.1</sub> measurements were performed by applying 1 s test pulses ranging between −120 and +30 mV, in 10 mV increments, from a holding potential of −40 mV, and with series resistance compensation of at least 70%. Steady state current at the end of the pulse was normalized to cell capacitance and plotted versus test potential (corrected for liquid junction potential). Extracellular solution contained 140 mM NaCl, 5 mM KCl, 1 mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub>, 6 mM glucose, 17.5 mM NaHCO<sub>3</sub>, 15 mM HEPES, pH 7.4/NaOH. Pipette solution contained 125 mM potassium gluconate, 10 mM KCl, 5 mM HEPES, 5 mM EGTA, 2 mM MgCl<sub>2</sub>, 0.6 mM CaCl<sub>2</sub>, 4 mM Na<sub>2</sub>ATP, pH 7.20/KOH.</p>
<p id="Par26">PA-6 (Fig. <xref ref-type="fig" rid="Fig1">1a</xref>) was custom synthesized by Endotherm GmbH (Saarbrücken, Germany).<fig id="Fig1"><label>Fig. 1</label><caption><p>
<bold>a</bold> Chemical structure of PA-6 (drawn in Accelrys Draw 4.1). <bold>b</bold> Compound PA-6 docked into a homology model of K<sub>IR</sub>2.1. Three subunits are shown in side view; the fourth is removed for clarity. The location of mutations V93I (M1 helix) and D172N (M2 helix) are depicted in spheres representation. PA-6, bound to the cytoplasmic domain, is shown as cyan spheres. Nitrogen atoms are coloured blue, oxygen atoms are shown in red. Approximate membrane boundaries are indicated as black dotted lines. The figure was generated with Pymol</p></caption><graphic id="MO1" xlink:href="12929_2017_352_Fig1_HTML"></graphic></fig>
</p>
</sec>
<sec id="Sec6">
<title>Western blot</title>
<p id="Par27">HEK293T cells were grown in 60 mm culture dishes containing 3 mL DMEM supplemented with 10% FCS, L-Glutamine and Pen-Strep, and transfected using linear polyethylenimine (PEI) (PolysciencesInc, Eppelheim, Germany) as described earlier [<xref ref-type="bibr" rid="CR29">29</xref>]. Cell lysates were prepared in buffer D (20 mM HEPES, 125 mM NaCl, 10% glycerol, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, and 1% Triton X-100, pH 7.6, supplemented with 1 mM PMSF and 10 μg/mL aprotinin). 20 μg protein lysate was separated by 10% SDS-PAGE and blotted onto nitrocellulose membrane. Ponceau staining was used to reveal equal protein loading and subsequent quantification. Blots were blocked with 5% (<italic>v</italic>/v) chicken egg yolk in TBST (20 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.05% (<italic>v</italic>/v) Tween-20) for 1 h at room temperature. K<sub>IR</sub>2.1 WT and mutants were detected by N-terminal K<sub>IR</sub>2.1 antibody (Santa Cruz Biotechnology, Dallas Tx, USA, cat. No. sc-18708) and peroxidase-conjugated donkey anti-goat secondary antibody (Jackson ImmunoResearch, West Grove, PA, cat. No. 705-035-003) followed by ECL detection procedure (GE Healthcare, Hoevelaken, The Netherlands). For quantification purposes, untransfected HEK293T cells were used as blank and protein levels were normalized to ponceau staining levels. Differences between group averages were tested by using a one-way ANOVA with a Bonferroni’s post-hoc test.</p>
</sec>
<sec id="Sec7">
<title>Immunofluorescence microscopy</title>
<p id="Par28">HEK293T and MES-1 cells were cultured on pre-coated (0.1% gelatin) glass coverslips and transfected using Lipofectamin (Invitrogen, Breda, The Netherlands). Cell fixation, immunolabeling and imaging were performed exactly as described earlier [<xref ref-type="bibr" rid="CR29">29</xref>]. Antibodies used were anti-K<sub>IR</sub>2.l (1:250; Santa Cruz Biotechnology, cat. no. sc-18708) and anti-Pan Cadherin (1:800, Sigma-Aldrich, St. Louis MO, USA, cat. No. C1821). HEK293T cells were imaged by confocal microscopy using a Zeiss LSM 700 confocal microscope (Carl Zeiss Microscopy GmbH, Germany) equipped with a 63× oil immersion objective (NA 1.4). Excitation was performed with an air-cooled Argon ion laser (LASOS, RMC 7812Z, 488 nm) for GFP and a HeNE (LASOS, SAN 7450A, 543 nm) laser for DyLight. MES-1 cells were imaged using a conventional Nikon eclipse 80i light microscopy equipped with a 40× objective (NA 0.75).</p>
</sec>
</sec>
<sec id="Sec8">
<title>Results</title>
<sec id="Sec9">
<title>V93I and D172N mutations do not interfere with the PA-6 K<sub>IR</sub>2.1 channel interaction</title>
<p id="Par29">To determine whether V93I or D172N mutations in the K<sub>IR</sub>2.1 channel may interfere with PA-6 current block, mutations and PA-6 channel interaction were modelled. Figure <xref ref-type="fig" rid="Fig1">1b</xref> shows the docking result of PA-6 into the V93I/D172N double mutant homology model of K<sub>IR</sub>2.1. The results demonstrate that these mutations are unlikely to influence binding of PA-6 to the previously identified binding site in the cytoplasmic domain [<xref ref-type="bibr" rid="CR20">20</xref>]. Both mutations are located in the transmembrane domain and thus &gt;30 Å away from the binding site.</p>
</sec>
<sec id="Sec10">
<title>PA-6 inhibits inward rectifier currents carried by V93I and D172N mutant K<sub>IR</sub>2.1 channels</title>
<p id="Par30">To determine the functional effects of PA-6 on the K<sub>IR</sub>2.1 gain-of-function mutant channels, expression constructs were transiently transfected into HEK293T cells. Currents were measured in the inside-out mode, to allow for direct access of PA-6 to the cytoplasmic channel pore, of the patch-clamp technique using a ramp-protocol from −100 to +100 mV. PA-6 dose dependently inhibited inward rectifier inward (at −80 mV) and outward (at +50 mV) currents carried by WT, V93I and D172N K<sub>IR</sub>2.1 channels (Fig. <xref ref-type="fig" rid="Fig2">2a</xref>). A small voltage dependency of block was observed for WT and both mutant channels as reflected in small, but not significant, changes in IC<sub>50</sub> values obtained at −80 and +50 mV for each K<sub>IR</sub>2.1 type. Interestingly, in contrast to WT and V93I, D172N outward current was less sensitive for PA-6 block than inward current. Whereas WT and V93I displayed virtually identical dose dependent block (IC<sub>50</sub> of 52.9 and 58.0 nM at −80 mV and 35.5 and 43.6 nM at +50 mV for WT and V93I channels respectively), D172N channels were approximately two to three fold less sensitive (IC<sub>50</sub> 109.3 nM at −80 mV and 128.9 nM at +50 mV) (Fig. <xref ref-type="fig" rid="Fig2">2b</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>PA-6 dose dependently inhibits I<sub>K1</sub> currents carried by homotypic wild-type (WT), V93I and D172N K<sub>IR</sub>2.1 channels measured in the inside out mode. <bold>a</bold> Steady state K<sub>IR</sub>2.1 current traces from WT, V93I and D172N K<sub>IR</sub>2.1 channel containing inside-out patches elicited by a voltage ramp protocol from −100 to 100 mV, under baseline conditions (C) and upon application of 10, 100 and 1000 nM of PA-6. Measurements were performed using symmetrical high potassium concentrations at both sides of the patch. <bold>b</bold> IC<sub>50</sub> curves of PA-6 for the inward (at −80 mV) and outward (at +50 mV) K<sub>IR</sub>2.1 currents of WT (<italic>n</italic> = 10), V93I (<italic>n</italic> = 9) and D172N (<italic>n</italic> = 11) channel containing patches. Error bars indicate s.e.m</p></caption><graphic id="MO2" xlink:href="12929_2017_352_Fig2_HTML"></graphic></fig>
</p>
<p id="Par31">Using the whole cell mode of the patch clamp technique, gain-of-function of D172N mutant became apparent as a change in the rectification index ((1-(outward current at −40 mV divided by inward current at −100 mV)) [<xref ref-type="bibr" rid="CR30">30</xref>], not correct for liquid junction potential) from 0.83 ± 0.11 (<italic>n</italic> = 9, mean ± s.d.) for WT channels to 0.70 ± 0.06 (<italic>n</italic> = 10, <italic>P</italic> &lt; 0.01) in D172N channels (Fig. <xref ref-type="fig" rid="Fig3">3a</xref>), in accordance with earlier findings [<xref ref-type="bibr" rid="CR2">2</xref>]. No change in rectification index of V93I (0.87 ± 0.09, <italic>n</italic> = 10, n.s.) was found. In addition, whereas PA-6 sensitivity was decreased in the whole cell mode, compared to the inside-out mode no differences were observed between WT and mutant channels (Fig. <xref ref-type="fig" rid="Fig3">3b</xref>). In the presence of 1 μM of PA-6, a non-significant (n.s.) reduction of outward I<sub>K1</sub> at −50 mV by 28 ± 36%, 18 ± 20% and 10 ± 6%, for WT, V93I and D172N channels respectively was observed. At 3 μM, PA-6 significantly inhibited I<sub>K1</sub> at −50 mV by 94 ± 6% (<italic>P</italic> &lt; 0.05), 77 ± 29% (<italic>P</italic> &lt; 0.05) and 86 ± 7% (<italic>P</italic> &lt; 0.01), for WT, V93I and D172N channels, respectively. For the inward current at −110 mV, 1 and 3 μM PA-6 inhibited I<sub>K1</sub> by 30 ± 16% (n.s.) and 68 ± 15% (<italic>P</italic> &lt; 0.01), 28 ± 14% (<italic>P</italic> &lt; 0.05) and 64 ± 4% (<italic>P</italic> &lt; 0.001), 30 ± 10% (n.s.) and 83 ± 1% (<italic>P</italic> &lt; 0.01) for WT, V93I and D172N channels, respectively. We conclude that in the whole cell mode, PA-6 inhibits WT, V93I and D172N channels with similar efficacy resulting in IC<sub>50</sub> values between 1 and 3 μM.<fig id="Fig3"><label>Fig. 3</label><caption><p>PA-6 dose dependently inhibits I<sub>K1</sub> currents carried by homotypic wild-type (WT), V93I and D172N K<sub>IR</sub>2.1 channels in the whole cell mode. <bold>a</bold> Comparison of whole cell IV-curves obtained from HEK293 cells expressing WT (<italic>closed circles</italic>), V93I (<italic>open squares</italic>) or D172N (<italic>closed triangles</italic>) K<sub>IR</sub>2.1 channels. Currents were elicited by 1 s test pulses ranging between −120 and +30 mV, in 10 mV increments and correct for liquid junction potential. <bold>b</bold> Whole cell steady state current IV-curves from WT, V93I and D172N K<sub>IR</sub>2.1 channels expressed in HEK293 under control (<italic>closed circles</italic>), 1 μM PA-6 (<italic>open squares</italic>) and 3 μM PA-6 conditions. Voltage protocol as in panel <bold>a</bold>
</p></caption><graphic id="MO3" xlink:href="12929_2017_352_Fig3_HTML"></graphic></fig>
</p>
</sec>
<sec id="Sec11">
<title>V93I and D172N mutations do not affect PA-6 mediated increase in K<sub>IR</sub>2.1 expression and intracellular accumulation</title>
<p id="Par32">When applied at concentrations of 10 μM, PA-6 is able to enhance expression of WT K<sub>IR</sub>2.1 in cells stably expressing GFP-tagged K<sub>IR</sub>2.1 [<xref ref-type="bibr" rid="CR20">20</xref>]. To assess the effects of PA-6 on expression of WT and mutant channels in transiently transfected HEK293T cells, cultures were treated with 0, 0.2, 1 and 5 μM PA-6 for 24 h after which expression levels were detected by Western blot analysis. PA-6 treatment increased K<sub>IR</sub>2.1 expression levels for all three variants (Fig. <xref ref-type="fig" rid="Fig4">4a</xref>). Strongest responses were obtained with 5 μM PA-6 added to the medium that reached significance for WT (<italic>P</italic> &lt; 0.001) and V931 (<italic>P</italic> &lt; 0.01) whereas a trend was observed for D172N (<italic>P</italic> = 0.09) (Fig. <xref ref-type="fig" rid="Fig4">4b</xref>). Lower concentrations of PA-6 did not result in significant increased expression.<fig id="Fig4"><label>Fig. 4</label><caption><p>PA-6 application for 24 h increases WT, V93I and D172N K<sub>IR</sub>2.1 channel expression. <bold>a</bold> Dose-dependent (0-5 μM) effect of 24 h exposure to PA-6 on HEK293T cells transiently transfected with WT, V93I and D172N K<sub>IR</sub>2.1 channels. NT indicates non-transfected cells. Ponceau staining was used as loading control for quantification (<bold>b</bold>) Summarized quantification data from WT (<italic>n</italic> = 11 independent western blots), V93I (<italic>n</italic> = 11) and D172N (<italic>n</italic> = 13) are shown in mean ± s.e.m. *** <italic>P</italic> &lt; 0.001 vs. control, ** <italic>P</italic> &lt; 0.01 vs. control, #<italic>P</italic> = 0.09 vs. control</p></caption><graphic id="MO4" xlink:href="12929_2017_352_Fig4_HTML"></graphic></fig>
</p>
<p id="Par33">To detect the subcellular location of the WT, V93I and D172N channels following PA-6 application, confocal immunofluorescent microscopy was performed in HEK293T cells. In non-treated control cells, both WT and mutant channels were mainly expressed at the plasma membrane, where they demonstrate colocalization with Cadherin (Fig. <xref ref-type="fig" rid="Fig5">5</xref> left column), whereas PA-6 treatment (1 μM) for 24 h induced an intracellular increase of the channel proteins in small aggregates, irrespectively whether these are WT or mutant (Fig. <xref ref-type="fig" rid="Fig5">5</xref>, middle column). PA-6 treatment at 5 μM for 24 further increased the level of intracellular accumulation (Fig. <xref ref-type="fig" rid="Fig5">5</xref>, right column). To exclude any potential effect of cell-type specific response, immune detection was also performed in the mesoderm-like cell line MES-1 as shown previously [<xref ref-type="bibr" rid="CR29">29</xref>] which yielded similar responses (Fig. <xref ref-type="fig" rid="Fig6">6</xref>). In control cells, WT and mutant channels were localized mainly at the plasma membrane, whereas 5 μM of PA-6 (24 h) resulted in intracellular accumulation, in a fashion similar as for chloroquine although the latter treatment resulted in aggregates more equally in size [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR31">31</xref>].<fig id="Fig5"><label>Fig. 5</label><caption><p>PA-6 treatment for 24 h induces intracellular K<sub>IR</sub>2.1 accumulation of WT, V93I and D172N channel proteins in HEK293T cells. Confocal microscopy optical slices (0.7-0.8 μm) displaying K<sub>IR</sub>2.1 (<italic>green</italic>) localization in HEK293T cells transfected with WT, V93A and D172N channels under control conditions and following 24 h of PA-6 (1 and 5 μM). Cadherin (<italic>red</italic>) co-staining identifies the position of the plasma membrane. DAPI (<italic>blue</italic>) is used to visualize nuclei. Scale bars represent 10 μm</p></caption><graphic id="MO5" xlink:href="12929_2017_352_Fig5_HTML"></graphic></fig>
<fig id="Fig6"><label>Fig. 6</label><caption><p>PA-6 treatment for 24 h induces intracellular K<sub>IR</sub>2.1 accumulation of WT, V93I and D172N channel proteins in MES-1 cells. Whole cell K<sub>IR</sub>2.1 (<italic>green</italic>) and Cadherin (<italic>red</italic>) localization in MES-1 cells transfected with WT, V93I or D172N channels in non-treated (control), PA-6 (5 μM, 24 h) or chloroquine (10 μM, 24 h) conditions imaged by conventional fluorescent microscopy. DAPI (<italic>blue</italic>) was used to identify nuclei. Scale bars represent 10 μm</p></caption><graphic id="MO6" xlink:href="12929_2017_352_Fig6_HTML"></graphic></fig>
</p>
</sec>
</sec>
<sec id="Sec12">
<title>Discussion</title>
<p id="Par34">Due to the high risk of sudden cardiac death, ICD implantation is indicated in congenital SQT patients. However, pharmacological treatment is warranted in young children not amenable for ICD implantation, in patients refusing an ICD and as a bridge to ICD therapy [<xref ref-type="bibr" rid="CR10">10</xref>]. In congenital SQT patients, responsiveness of the QTc interval towards class IC and class III antiarrhythmics were unsatisfactory. SQT patients did not show anticipated responses to flecainide, d-sotalol or ibutilide [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Only hydroquinidine was able to prolong QTc to borderline or normal duration [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Short QT syndrome type 1 (SQT1) results from gain-of-function mutations in the K<sub>v</sub>11.1 (hERG) channel encoded by the <italic>KCNH2</italic> gene, and is the best studied SQT subtype with respect to pharmacological treatment. The N588K gain-of-function mutation appears a hotspot in SQT1. Interestingly, N558K channels were less sensitive for Class III antiarrhythmics like d-sotalol [<xref ref-type="bibr" rid="CR34">34</xref>], and E-4031 (11-fold) [<xref ref-type="bibr" rid="CR11">11</xref>]. Accordingly, d-sotalol was unable to prolong the QT interval in SQT1 N558K patients [<xref ref-type="bibr" rid="CR34">34</xref>]. In contrast, disopyramide (1.5-fold) and hydroquinidine (3.5-fold) displayed smaller differences in IC<sub>50</sub> values for WT and N558K K<sub>v</sub>11.1 channels, respectively. Clinical studies indeed showed favourable responses to hydroquinidine in SQT1 [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR35">35</xref>], whereas QTc prolongation in non-K<sub>v</sub>11.1 SQT patients was smaller [<xref ref-type="bibr" rid="CR33">33</xref>]. The SQT2 associated mutation V307L in the K<sub>v</sub>7.1 channel was shown to be equally sensitive for mefloquine as its WT variant, on which basis the authors suggested that this drug may be an effective treatment strategy in this patient population [<xref ref-type="bibr" rid="CR14">14</xref>]. Interestingly, the same V307L mutation increased the IC<sub>50</sub> value for the K<sub>v</sub>7.1 inhibitor Chromanol293B by 7-fold [<xref ref-type="bibr" rid="CR36">36</xref>], indicating again that a mutation specific pharmacological approach is favourable. The SQT3 associated D172N mutation in K<sub>IR</sub>2.1 was equally sensitive for chloroquine (1.2-3.3 μM) as its WT counterpart (1.4-2.4 μM) measured in the whole cell mode [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Here we demonstrate that upon acute superfusion, PA-6 is also able to inhibit D172N mutant K<sub>IR</sub>2.1 channel with an IC<sub>50</sub> only two to three fold higher than that of WT channels, measured in the inside-out mode, and that potency of inhibition of the V93I channel was similar as for WT. In the whole cell mode, acute PA-6 superfusion inhibits WT, V93I and D172N with similar efficacy. Therefore, PA-6 could potentially be effective in addressing SQT3 and AF associated with each of these two mutations.</p>
<p id="Par35">In contrast to PA-6, chloroquine suffers from lack of specificity as it significantly inhibits delayed rectifier (I<sub>Kr</sub>), sodium (I<sub>Na</sub>) and l-type calcium (I<sub>Ca-l</sub>) currents [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. Upon long-term exposure however, both chloroquine and PA-6 are able to increase K<sub>IR</sub>2.1 channel expression [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. However, due to its lower potency, the concentrations at which chloroquine affected trafficking (5 μM) are slightly closer to its IC<sub>50</sub> for acute blockade than seen for PA-6. Furthermore, the majority of PA-6 induced increase of K<sub>IR</sub>2.1 channel expression as detected by Western blot upon chronic exposure results from intracellular accumulation instead of functional channels at the plasma membrane.</p>
<p id="Par36">The acute channel inhibiting effect of a drug may or may be not be correlated with its chronic effect on ion channel expression. For example, pentamidine inhibits the K<sub>IR</sub>2.1 channel acutely and decreases K<sub>IR</sub>2.1 expression upon chronic treatment [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>], but its structural derivative PA-6 inhibits K<sub>IR</sub>2.1 currents acutely while it increases channel expression chronically as shown here and previously [<xref ref-type="bibr" rid="CR20">20</xref>]. In the former case, both drug effects are additive and maybe synergistic. In the case of PA-6, acute and chronic effects are opposite, but at 1 and 3 μM, the acute effects on current inhibition are stronger than the increases in channel expression levels upon chronic exposure. Only upon acute termination of PA-6 application, the effects on expression may temporarily prevail over the acute blocking effect (or absence thereof) resulting in enhanced I<sub>K1</sub>.</p>
</sec>
<sec id="Sec13">
<title>Limitations</title>
<p id="Par37">The effects of PA-6 on WT, V93I and D172N K<sub>IR</sub>2.1 channels have only been tested in ectopic expression systems and therefore the effects of their blockade on cardiac action potential characteristics could not be evaluated.</p>
</sec>
<sec id="Sec14">
<title>Conclusions</title>
<p id="Par38">In the K<sub>IR</sub>2.1 ion channel, V93I and D172N gain-of-function mutations do not blunt the inhibitory capacity of PA-6. PA-6 application results in enhanced K<sub>IR</sub>2.1 protein expression, mainly localized in intracellular aggregates. From our findings presented here, we conclude that PA-6 may be considered for further preclinical evaluation for treatment of congenital SQT3 and AF.</p>
</sec>
</body>
<back>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>AF</term>
<def>
<p id="Par5">Atrial fibrillation</p>
</def>
</def-item>
<def-item>
<term>GFP</term>
<def>
<p id="Par6">Green fluorescent protein</p>
</def>
</def-item>
<def-item>
<term>HEK</term>
<def>
<p id="Par7">Human embryonal kidney</p>
</def>
</def-item>
<def-item>
<term>I<sub>Ca-l</sub></term>
<def>
<p id="Par8">L-type Calcium current</p>
</def>
</def-item>
<def-item>
<term>ICD</term>
<def>
<p id="Par9">Implantable cardioverter-defibrillator</p>
</def>
</def-item>
<def-item>
<term>I<sub>K1</sub></term>
<def>
<p id="Par10">Inward rectifier potassium current</p>
</def>
</def-item>
<def-item>
<term>I<sub>KACh</sub></term>
<def>
<p id="Par11">Acetylcholine activated inward rectifier potassium current</p>
</def>
</def-item>
<def-item>
<term>I<sub>Kr</sub></term>
<def>
<p id="Par12">Delayed rectifier current</p>
</def>
</def-item>
<def-item>
<term>I<sub>Na</sub></term>
<def>
<p id="Par13">Sodium current</p>
</def>
</def-item>
<def-item>
<term>PA-6</term>
<def>
<p id="Par14">Pentamidine analogue-6</p>
</def>
</def-item>
<def-item>
<term>SQTx</term>
<def>
<p id="Par15">Short QT syndrome type x</p>
</def>
</def-item>
<def-item>
<term>WT</term>
<def>
<p id="Par16">Wild-type</p>
</def>
</def-item>
</def-list>
</glossary>
<ack>
<title>Acknowledgements</title>
<p>Y.J. is the recipient of a scholarship from the Chinese Scholarship Council. We thank Drs. M.B. Rook and T.P. de Boer (Dept of Medical Physiology, University Medical Center Utrecht, The Netheralands) for fruitful discussions on electrophysiological measurements, and Dr. I.S. Grigoriev (Dept. of Cell Biology, Utrecht University, The Netherlands) for technical assistance concerning confocal microscopy.</p>
<sec id="FPar1">
<title>Funding</title>
<p id="Par39">This work was supported by the Chinese Scholarship Council (CSC).</p>
</sec>
<sec id="FPar2">
<title>Availability of data and materials</title>
<p id="Par40">Not applicable.</p>
</sec>
</ack>
<notes notes-type="author-contribution">
<title>Authors’ contributions</title>
<p>YJ, MGV, HT and MJCH performed electrophysiological recordings; KD, GvH generated V93I and D172N expression constructs; EMZP and ASW performed and analyzed molecular modelling; JZ performed and analyzed western blot experiments; FLR and MAGvdH performed and analyzed the subcellular localization experiments; MAGvdH and YJ designed the study. YJ, MAGvdH, GvH and ASW wrote the manuscript. All authors read and approved the manuscript.</p>
</notes>
<notes notes-type="COI-statement">
<sec id="FPar3">
<title>Ethics approval and consent to participate</title>
<p id="Par41">Not applicable.</p>
</sec>
<sec id="FPar4">
<title>Consent for publication</title>
<p id="Par42">Not applicable.</p>
</sec>
<sec id="FPar5">
<title>Competing interests</title>
<p id="Par43">The authors declare that they have no competing interest.</p>
</sec>
<sec id="FPar6">
<title>Publisher’s Note</title>
<p id="Par44">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</sec>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hibino</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Inanobe</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Furutani</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Murakami</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Findlay</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Kurachi</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Inwardly rectifying potassium channels: their structure, function, and physiological roles</article-title>
<source/>Physiol Rev
          <year>2010</year>
<volume>90</volume>
<fpage>291</fpage>
<lpage>366</lpage>
<pub-id pub-id-type="doi">10.1152/physrev.00021.2009</pub-id>
<pub-id pub-id-type="pmid">20086079</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Priori</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Pandit</surname>
<given-names>SV</given-names>
</name>
<name>
<surname>Rivolta</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Berenfeld</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Ronchetti</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Dhamoon</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Napolitano</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Anumonwo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>di Barletta</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Gudapakkam</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bosi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Stramba-Badiale</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jalife</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene</article-title>
<source/>Circ Res
          <year>2005</year>
<volume>96</volume>
<fpage>800</fpage>
<lpage>807</lpage>
<pub-id pub-id-type="doi">10.1161/01.RES.0000162101.76263.8c</pub-id>
<pub-id pub-id-type="pmid">15761194</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ambrosini</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sicca</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Brignone</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>D'Adamo</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Napolitano</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Servettini</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Moro</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Ruan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Guglielmi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Pieroni</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Servillo</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Lanciotti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Valvo</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Catacuzzeno</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Franciolini</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Molinari</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Marchese</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Grottesi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Guerrini</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Santorelli</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Priori</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pessia</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Genetically induced dysfunctions of Kir2.1 channels: implications for short QT3 syndrome and autism-epilepsy phenotype</article-title>
<source/>Hum Mol Genet
          <year>2014</year>
<volume>23</volume>
<fpage>4875</fpage>
<lpage>4886</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddu201</pub-id>
<pub-id pub-id-type="pmid">24794859</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Bendahhou</surname>
<given-names>S</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Larroque</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Eurlings</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Barhanin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Kir2.1 gain-of-function mutation underlies familial atrial fibrillation</article-title>
<source/>Biochem Biophys Res Commun
          <year>2005</year>
<volume>332</volume>
<fpage>1012</fpage>
<lpage>1019</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2005.05.054</pub-id>
<pub-id pub-id-type="pmid">15922306</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ruan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Pandit</surname>
<given-names>SV</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Berenfeld</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Blaufox</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cerrone</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Noujaim</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Denegri</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jalife</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Priori</surname>
<given-names>SG</given-names>
</name>
</person-group>
<article-title>KCNJ2 mutation in short QT syndrome 3 results in atrial fibrillation and ventricular proarrhythmia</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2013</year>
<volume>110</volume>
<fpage>4291</fpage>
<lpage>4296</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1218154110</pub-id>
<pub-id pub-id-type="pmid">23440193</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hattori</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Makiyama</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Akao</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ehara</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ohno</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Iguchi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nishio</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Sasaki</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Itoh</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yokode</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kita</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Horie</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kimura</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>A novel gain-of-function KCNJ2 mutation associated with short-QT syndrome impairs inward rectification of Kir2.1 currents</article-title>
<source/>Cardiovasc Res
          <year>2012</year>
<volume>93</volume>
<fpage>666</fpage>
<lpage>673</lpage>
<pub-id pub-id-type="doi">10.1093/cvr/cvr329</pub-id>
<pub-id pub-id-type="pmid">22155372</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Priori</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Wilde</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Horie</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Behr</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Berul</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Blom</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Brugada</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chiang</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Huikuri</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kannankeril</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Krahn</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Leenhardt</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Moss</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Shimizu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Tomaselli</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Tracy</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013</article-title>
<source/>Heart Rhythm
          <year>2013</year>
<volume>10</volume>
<fpage>1932</fpage>
<lpage>1963</lpage>
<pub-id pub-id-type="doi">10.1016/j.hrthm.2013.05.014</pub-id>
<pub-id pub-id-type="pmid">24011539</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patel</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>GX</given-names>
</name>
<name>
<surname>Antzelevitch</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Short QT syndrome: from bench to bedside</article-title>
<source/>Circ Arrhythm Electrophysiol
          <year>2010</year>
<volume>3</volume>
<fpage>401</fpage>
<lpage>408</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCEP.109.921056</pub-id>
<pub-id pub-id-type="pmid">20716721</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pérez Riera</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Paixão-Almeida</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Barbosa-Barros</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Yanowitz</surname>
<given-names>FG</given-names>
</name>
<name>
<surname>Baranchuk</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dubner</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Palandri Chagas</surname>
<given-names>AC</given-names>
</name>
</person-group>
<article-title>Congenital short QT syndrome: landmarks of the newest arrhythmogenic cardiac channelopathy</article-title>
<source/>Cardiol J
          <year>2013</year>
<volume>20</volume>
<fpage>464</fpage>
<lpage>471</lpage>
<pub-id pub-id-type="doi">10.5603/CJ.a2013.0052</pub-id>
<pub-id pub-id-type="pmid">23677719</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patel</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Antzelevitch</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Pharmacological approach to the treatment of long and short QT syndromes</article-title>
<source/>Pharmacol Ther
          <year>2008</year>
<volume>118</volume>
<fpage>138</fpage>
<lpage>151</lpage>
<pub-id pub-id-type="doi">10.1016/j.pharmthera.2008.02.001</pub-id>
<pub-id pub-id-type="pmid">18378319</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McPate</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Duncan</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Witchel</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Hancox</surname>
<given-names>JC</given-names>
</name>
</person-group>
<article-title>Disopyramide is an effective inhibitor of mutant HERG K<sup>+</sup> channels involved in variant 1 short QT syndrome</article-title>
<source/>J Mol Cell Cardiol
          <year>2006</year>
<volume>41</volume>
<fpage>563</fpage>
<lpage>566</lpage>
<pub-id pub-id-type="doi">10.1016/j.yjmcc.2006.05.021</pub-id>
<pub-id pub-id-type="pmid">16842817</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>El Harchi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>McPate</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hancox</surname>
<given-names>JC</given-names>
</name>
</person-group>
<article-title>Action potential clamp and chloroquine sensitivity of mutant Kir2.1 channels responsible for variant 3 short QT syndrome</article-title>
<source/>J Mol Cell Cardiol
          <year>2009</year>
<volume>47</volume>
<fpage>743</fpage>
<lpage>747</lpage>
<pub-id pub-id-type="doi">10.1016/j.yjmcc.2009.02.027</pub-id>
<pub-id pub-id-type="pmid">19285083</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lopez-Izquierdo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ponce-Balbuena</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ferrer</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sachse</surname>
<given-names>FB</given-names>
</name>
<name>
<surname>Tristani-Firouzi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sanchez-Chapula</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Chloroquine blocks a mutant Kir2.1 channel responsible for short QT syndrome and normalizes repolarization properties in silico</article-title>
<source/>Cell Physiol Biochem
          <year>2009</year>
<volume>24</volume>
<fpage>153</fpage>
<lpage>160</lpage>
<pub-id pub-id-type="doi">10.1159/000233241</pub-id>
<pub-id pub-id-type="pmid">19710529</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>El Harchi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>McPate</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hancox</surname>
<given-names>JC</given-names>
</name>
</person-group>
<article-title>Action potential clamp and mefloquine sensitivity of recombinant ‘I<sub>KS</sub>’ channels incorporating the V307L KCNQ1 mutation</article-title>
<source/>J Physiol Pharmacol
          <year>2010</year>
<volume>61</volume>
<fpage>123</fpage>
<lpage>131</lpage>
<pub-id pub-id-type="pmid">20436212</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Camm</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Lip</surname>
<given-names>GY</given-names>
</name>
<name>
<surname>De Caterina</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Savelieva</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Atar</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hohnloser</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Hindricks</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kirchhof</surname>
<given-names>P</given-names>
</name>
<collab>ESC Committee for Practice Guidelines (CPG)</collab>
</person-group>
<article-title>2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association</article-title>
<source/>Eur Heart J
          <year>2012</year>
<volume>33</volume>
<fpage>2719</fpage>
<lpage>2747</lpage>
<pub-id pub-id-type="doi">10.1093/eurheartj/ehs253</pub-id>
<pub-id pub-id-type="pmid">22922413</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Workman</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Rankin</surname>
<given-names>AC</given-names>
</name>
</person-group>
<article-title>Mechanisms of termination and prevention of atrial fibrillation by drug therapy</article-title>
<source/>Pharmacol Ther
          <year>2011</year>
<volume>131</volume>
<fpage>221</fpage>
<lpage>241</lpage>
<pub-id pub-id-type="doi">10.1016/j.pharmthera.2011.02.002</pub-id>
<pub-id pub-id-type="pmid">21334377</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ehrlich</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Nattel</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Novel approaches for pharmacological management of atrial fibrillation</article-title>
<source/>Drugs
          <year>2009</year>
<volume>69</volume>
<fpage>757</fpage>
<lpage>774</lpage>
<pub-id pub-id-type="doi">10.2165/00003495-200969070-00001</pub-id>
<pub-id pub-id-type="pmid">19441867</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Noujaim</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Stuckey</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Ponce-Balbuena</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ferrer-Villada</surname>
<given-names>T</given-names>
</name>
<name>
<surname>López-Izquierdo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pandit</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Calvo</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Grzeda</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Berenfeld</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Chapula</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Jalife</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Specific residues of the cytoplasmic domains of cardiac inward rectifier potassium channels are effective antifibrillatory targets</article-title>
<source/>FASEB J
          <year>2010</year>
<volume>24</volume>
<fpage>4302</fpage>
<lpage>4312</lpage>
<pub-id pub-id-type="doi">10.1096/fj.10-163246</pub-id>
<pub-id pub-id-type="pmid">20585026</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Filgueiras-Rama</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Martins</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Mironov</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yamazaki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Calvo</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Ennis</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Bandaru</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Noujaim</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Kalifa</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Berenfeld</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Jalife</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Chloroquine terminates stretch-induced atrial fibrillation more effectively than flecainide in the sheep heart</article-title>
<source/>Circ Arrhythm Electrophysiol
          <year>2012</year>
<volume>5</volume>
<fpage>561</fpage>
<lpage>570</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCEP.111.966820</pub-id>
<pub-id pub-id-type="pmid">22467674</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takanari</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Nalos</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Stary-Weinzinger</surname>
<given-names>A</given-names>
</name>
<name>
<surname>de Git</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Varkevisser</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Linder</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Houtman</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Peschar</surname>
<given-names>M</given-names>
</name>
<name>
<surname>de Boer</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>Tidwell</surname>
<given-names>RR</given-names>
</name>
<name>
<surname>Rook</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Vos</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>van der Heyden</surname>
<given-names>MAG</given-names>
</name>
</person-group>
<article-title>Efficient and specific cardiac I<sub>K1</sub> inhibition by a new pentamidine analogue</article-title>
<source/>Cardiovasc Res
          <year>2013</year>
<volume>99</volume>
<fpage>203</fpage>
<lpage>214</lpage>
<pub-id pub-id-type="doi">10.1093/cvr/cvt103</pub-id>
<pub-id pub-id-type="pmid">23625347</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<mixed-citation publication-type="other">Ji Y, Varkevisser R, Opacic D, Bossu A, Kuiper M, Beekman JDM, Yang S, Khan AP, Dobrev D, Voigt N, Wang MZ, Verheule S, Vos MA, Van der Heyden MAG. The inward rectifier current inhibitor PA-6 terminates atrial fibrillation and does not cause ventricular arrhythmias in dedicated goat and dog models. Br J Pharmacol. 2017; doi:10.1111/bph.13869.</mixed-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Varkevisser</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Houtman</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Linder</surname>
<given-names>T</given-names>
</name>
<name>
<surname>de Git</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Beekman</surname>
<given-names>HD</given-names>
</name>
<name>
<surname>Tidwell</surname>
<given-names>RR</given-names>
</name>
<name>
<surname>IJzerman</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Stary-Weinzinger</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vos</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>van der Heyden</surname>
<given-names>MAG</given-names>
</name>
</person-group>
<article-title>Structure-activity relationships of pentamidine-affected ion channel trafficking and dofetilide mediated rescue</article-title>
<source/>Br J Pharmacol
          <year>2013</year>
<volume>169</volume>
<fpage>1322</fpage>
<lpage>1334</lpage>
<pub-id pub-id-type="doi">10.1111/bph.12208</pub-id>
<pub-id pub-id-type="pmid">23586323</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>January</surname>
<given-names>CT</given-names>
</name>
</person-group>
<article-title>Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome. Pharmacological and temperature effects</article-title>
<source/>J Biol Chem
          <year>1999</year>
<volume>274</volume>
<fpage>31123</fpage>
<lpage>31126</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.274.44.31123</pub-id>
<pub-id pub-id-type="pmid">10531299</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Reloj</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Nataraj</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Bartos</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Schroder</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Moss</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Ohno</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Horie</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>January</surname>
<given-names>CT</given-names>
</name>
<name>
<surname>Delisle</surname>
<given-names>BP</given-names>
</name>
</person-group>
<article-title>Pharmacological correction of long QT-linked mutations in KCNH2 (hERG) increases the trafficking of Kv11.1 channels stored in the transitional endoplasmic reticulum</article-title>
<source/>Am J Physiol Cell Physiol
          <year>2013</year>
<volume>305</volume>
<fpage>C919</fpage>
<lpage>C930</lpage>
<pub-id pub-id-type="doi">10.1152/ajpcell.00406.2012</pub-id>
<pub-id pub-id-type="pmid">23864605</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anderson</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Kuzmicki</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Childs</surname>
<given-names>RR</given-names>
</name>
<name>
<surname>Hintz</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Delisle</surname>
<given-names>BP</given-names>
</name>
<name>
<surname>January</surname>
<given-names>CT</given-names>
</name>
</person-group>
<article-title>Large-scale mutational analysis of K<sub>v</sub>11.1 reveals molecular insights into type 2 long QT syndrome</article-title>
<source/>Nat Commun
          <year>2014</year>
<volume>5</volume>
<fpage>5535</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms6535</pub-id>
<pub-id pub-id-type="pmid">25417810</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guex</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Peitsch</surname>
<given-names>MC</given-names>
</name>
</person-group>
<article-title>SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling</article-title>
<source/>Electrophoresis
          <year>1997</year>
<volume>18</volume>
<fpage>2714</fpage>
<lpage>2723</lpage>
<pub-id pub-id-type="doi">10.1002/elps.1150181505</pub-id>
<pub-id pub-id-type="pmid">9504803</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jansen</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>de Boer</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>Wolswinkel</surname>
<given-names>R</given-names>
</name>
<name>
<surname>van Veen</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Vos</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>van Rijen</surname>
<given-names>HV</given-names>
</name>
<name>
<surname>van der Heyden</surname>
<given-names>MAG</given-names>
</name>
</person-group>
<article-title>Lysosome mediated Kir2.1 breakdown directly influences inward rectifier current density</article-title>
<source/>Biochem Biophys Res Commun
          <year>2008</year>
<volume>367</volume>
<fpage>687</fpage>
<lpage>692</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2007.12.168</pub-id>
<pub-id pub-id-type="pmid">18182162</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Houtman</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Takanari</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kok</surname>
<given-names>BG</given-names>
</name>
<name>
<surname>van Eck</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Montagne</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Vos</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>de Boer</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>van der Heyden</surname>
<given-names>MAG</given-names>
</name>
</person-group>
<article-title>Experimental mapping of the canine KCNJ2 and KCNJ12 gene structures and functional analysis of the canine K<sub>IR</sub>2.2 ion channel</article-title>
<source/>Front Physiol
          <year>2012</year>
<volume>3</volume>
<fpage>9</fpage>
<pub-id pub-id-type="doi">10.3389/fphys.2012.00009</pub-id>
<pub-id pub-id-type="pmid">22363290</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<mixed-citation publication-type="other">Ji Y, Takanari H, Qile M, Nalos L, Houtman MJC, Romunde FL, Heukers R, Van Bergen en Henegouwen PMP, Vos MA, Van der Heyden MAG. Class III antiarrhythmic drugs amiodarone and dronedarone impair KIR2.1 backward trafficking. J Cell Mol Med. 2017; doi:10.1111/jcmm.13172.</mixed-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Anumonwo</surname>
<given-names>JMB</given-names>
</name>
</person-group>
<person-group person-group-type="editor">
<name>
<surname>Zipes</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Jalife</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Biophysical properties of inward rectifier potassium channels</article-title>
<source/>Cardiac electrophysiology: from cell to bedside
          <year>2004</year>
<publisher-loc>Philadelphia</publisher-loc>
<publisher-name>Saunders</publisher-name>
<fpage>112</fpage>
<lpage>119</lpage>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Varkevisser</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Houtman</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Waasdorp</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Man</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Heukers</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Takanari</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tieland</surname>
<given-names>RG</given-names>
</name>
<name>
<surname>van Bergen En Henegouwen</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Vos</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Heyden</surname>
<given-names>MAG</given-names>
</name>
</person-group>
<article-title>Inhibiting the clathrin-mediated endocytosis pathway rescues KIR2.1 downregulation by pentamidine</article-title>
<source/>Pflugers Arch
          <year>2013</year>
<volume>465</volume>
<fpage>247</fpage>
<lpage>259</lpage>
<pub-id pub-id-type="doi">10.1007/s00424-012-1189-5</pub-id>
<pub-id pub-id-type="pmid">23192368</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gaita</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Giustetto</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bianchi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Schimpf</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Haissaguerre</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Calò</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Brugada</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Antzelevitch</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Borggrefe</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wolpert</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Short QT syndrome: pharmacological treatment</article-title>
<source/>J Am Coll Cardiol
          <year>2004</year>
<volume>43</volume>
<fpage>1494</fpage>
<lpage>1499</lpage>
<pub-id pub-id-type="doi">10.1016/j.jacc.2004.02.034</pub-id>
<pub-id pub-id-type="pmid">15093889</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giustetto</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Schimpf</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mazzanti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Scrocco</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Maury</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Anttonen</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Probst</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Blanc</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Sbragia</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Dalmasso</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Borggrefe</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gaita</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Long-term follow-up of patients with short QT syndrome</article-title>
<source/>J Am Coll Cardiol
          <year>2011</year>
<volume>58</volume>
<fpage>587</fpage>
<lpage>595</lpage>
<pub-id pub-id-type="doi">10.1016/j.jacc.2011.03.038</pub-id>
<pub-id pub-id-type="pmid">21798421</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brugada</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Dumaine</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Cordeiro</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gaita</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Borggrefe</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Menendez</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Brugada</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pollevick</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Wolpert</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Burashnikov</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Matsuo</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Guerchicoff</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bianchi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Giustetto</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Schimpf</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Brugada</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Antzelevitch</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Sudden death associated with short-QT syndrome linked to mutations in HERG</article-title>
<source/>Circulation
          <year>2004</year>
<volume>109</volume>
<fpage>30</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="doi">10.1161/01.CIR.0000109482.92774.3A</pub-id>
<pub-id pub-id-type="pmid">14676148</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pirro</surname>
<given-names>E</given-names>
</name>
<name>
<surname>De Francia</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Banaudi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Riggi</surname>
<given-names>C</given-names>
</name>
<name>
<surname>De Martino</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Piccione</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Giustetto</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Racca</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Agnoletti</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Di Carlo</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Short QT syndrome in infancy. Therapeutic drug monitoring of hydroquinidine in a newborn infant</article-title>
<source/>Br J Clin Pharmacol
          <year>2011</year>
<volume>72</volume>
<fpage>982</fpage>
<lpage>984</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2125.2011.04055.x</pub-id>
<pub-id pub-id-type="pmid">21707701</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lerche</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bruhova</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Lerche</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Steinmeyer</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Strutz-Seebohm</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Lang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Busch</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Zhorov</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Seebohm</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Chromanol 293B binding in KCNQ1 (Kv7.1) channels involves electrostatic interactions with a potassium ion in the selectivity filter</article-title>
<source/>Mol Pharmacol
          <year>2007</year>
<volume>71</volume>
<fpage>1503</fpage>
<lpage>1511</lpage>
<pub-id pub-id-type="doi">10.1124/mol.106.031682</pub-id>
<pub-id pub-id-type="pmid">17347319</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sánchez-Chapula</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Salinas-Stefanon</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Torres-Jácome</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Benavides-Haro</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Navarro-Polanco</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Blockade of currents by the antimalarial drug chloroquine in feline ventricular myocytes</article-title>
<source/>J Pharmacol Exp Ther
          <year>2001</year>
<volume>297</volume>
<fpage>437</fpage>
<lpage>445</lpage>
<pub-id pub-id-type="pmid">11259572</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nalos</surname>
<given-names>L</given-names>
</name>
<name>
<surname>de Boer</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>Houtman</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Rook</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Vos</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>van der Heyden</surname>
<given-names>MAG</given-names>
</name>
</person-group>
<article-title>Inhibition of lysosomal degradation rescues pentamidine-mediated decreases of K<sub>IR</sub>2.1 ion channel expression but not that of K<sub>v</sub>11.1</article-title>
<source/>Eur J Pharmacol
          <year>2011</year>
<volume>652</volume>
<fpage>96</fpage>
<lpage>103</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejphar.2010.10.093</pub-id>
<pub-id pub-id-type="pmid">21114988</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Boer</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>Nalos</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Stary</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kok</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Houtman</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Antoons</surname>
<given-names>G</given-names>
</name>
<name>
<surname>van Veen</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Beekman</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>de Groot</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Opthof</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Rook</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Vos</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>van der Heyden</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>The anti-protozoal drug pentamidine blocks K<sub>IR</sub>2.x-mediated inward rectifier current by entering the cytoplasmic pore region of the channel</article-title>
<source/>Br J Pharmacol
          <year>2010</year>
<volume>159</volume>
<fpage>1532</fpage>
<lpage>1541</lpage>
<pub-id pub-id-type="doi">10.1111/j.1476-5381.2010.00658.x</pub-id>
<pub-id pub-id-type="pmid">20180941</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>